Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,483
archived clinical trials in
Influenza

Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
Clinical Research Solutions
mi
from
Franklin, TN
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
Clinical Research Solutions
mi
from
Franklin, TN
Click here to add this to my saved trials
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
Clinical Research Solutions
mi
from
Jackson, TN
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
Clinical Research Solutions
mi
from
Jackson, TN
Click here to add this to my saved trials
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
Clinical Research Solutions
mi
from
Smyrna, TN
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
Clinical Research Solutions
mi
from
Smyrna, TN
Click here to add this to my saved trials
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
Centex Studies Inc
mi
from
Houston, TX
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
Centex Studies Inc
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
Village Health Partners
mi
from
Plano, TX
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
Village Health Partners
mi
from
Plano, TX
Click here to add this to my saved trials
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
Paragon Rx Clinical
mi
from
Garden Grove, CA
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
Paragon Rx Clinical
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
Advanced Rx Clinical Research Group, Inc
mi
from
Westminster, CA
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
Advanced Rx Clinical Research Group, Inc
mi
from
Westminster, CA
Click here to add this to my saved trials
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
Great Lakes Medical Research
mi
from
Westfield, NY
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
Great Lakes Medical Research
mi
from
Westfield, NY
Click here to add this to my saved trials
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
Hospital General de Agudos J. M. Ramos Mejía
mi
from
Buenos Aires,
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
Hospital General de Agudos J. M. Ramos Mejía
mi
from
Buenos Aires,
Click here to add this to my saved trials
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage INC
mi
from
Omaha, NE
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage INC
mi
from
Omaha, NE
Click here to add this to my saved trials
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated:  12/31/1969
Clinical Research Solutions, PC
mi
from
Nashville, TN
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults
Status: Enrolling
Updated: 12/31/1969
Clinical Research Solutions, PC
mi
from
Nashville, TN
Click here to add this to my saved trials
Experimental AD4-H5-VTN Vaccine in Healthy Volunteers
Phase 1 Study of Safety and Immunogenicity of Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Experimental AD4-H5-VTN Vaccine in Healthy Volunteers
Phase 1 Study of Safety and Immunogenicity of Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors
A Pilot Study of Influenza Vaccine Efficacy in Patients With Central Nervous System Tumors
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors
A Pilot Study of Influenza Vaccine Efficacy in Patients With Central Nervous System Tumors
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety Study of FluMist With and Without Ampligen
A Phase I/II, Two-Staged, Single-Center, Randomized, Double-Blind, Antibody Titer Study to Assess Immunogenicity and Safety of FluMist® Intranasal Influenza Vaccine Administered With and Without a TLR-3 Agonist, Ampligen®.
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Safety Study of FluMist With and Without Ampligen
A Phase I/II, Two-Staged, Single-Center, Randomized, Double-Blind, Antibody Titer Study to Assess Immunogenicity and Safety of FluMist® Intranasal Influenza Vaccine Administered With and Without a TLR-3 Agonist, Ampligen®.
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17
Status: Enrolling
Updated:  12/31/1969
Emory Children's Center
mi
from
Atlanta, GA
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17
Status: Enrolling
Updated: 12/31/1969
Emory Children's Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17
Status: Enrolling
Updated:  12/31/1969
The Gamble Program for Clinical Studies, Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17
Status: Enrolling
Updated: 12/31/1969
The Gamble Program for Clinical Studies, Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17
Status: Enrolling
Updated:  12/31/1969
Saint Louis University - Doisy Research Center
mi
from
Saint Louis, MO
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17
Status: Enrolling
Updated: 12/31/1969
Saint Louis University - Doisy Research Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Austin, TX
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Miami, FL
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Edison, NJ
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Edison, NJ
Click here to add this to my saved trials
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Sherbrooke,
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Sherbrooke,
Click here to add this to my saved trials
Evaluating Immune Response to Seasonal FluMist in Healthy Adults
Evaluating Immune Response to Seasonal FluMist in Healthy Adults
Status: Enrolling
Updated:  12/31/1969
Malcom Randall VA Medical Center
mi
from
Gainesville, FL
Evaluating Immune Response to Seasonal FluMist in Healthy Adults
Evaluating Immune Response to Seasonal FluMist in Healthy Adults
Status: Enrolling
Updated: 12/31/1969
Malcom Randall VA Medical Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy
Influenza Vaccination Response in Patients With Non-Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy
Influenza Vaccination Response in Patients With Non-Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
High Dose Influenza Vaccine in Nursing Home - Pilot Study
High Dose Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes - A Pilot Evaluation
Status: Enrolling
Updated:  12/31/1969
Brown Univeristy
mi
from
Providence, RI
High Dose Influenza Vaccine in Nursing Home - Pilot Study
High Dose Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes - A Pilot Evaluation
Status: Enrolling
Updated: 12/31/1969
Brown Univeristy
mi
from
Providence, RI
Click here to add this to my saved trials
High Dose Influenza Vaccine in Nursing Home - Pilot Study
High Dose Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes - A Pilot Evaluation
Status: Enrolling
Updated:  12/31/1969
Insight Therapeutics
mi
from
Norfolk, VA
High Dose Influenza Vaccine in Nursing Home - Pilot Study
High Dose Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes - A Pilot Evaluation
Status: Enrolling
Updated: 12/31/1969
Insight Therapeutics
mi
from
Norfolk, VA
Click here to add this to my saved trials
Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults
Elucidation of the Mucosal Immune Responses to Live Attenuated Influenza Vaccine In Healthy Adults
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults
Elucidation of the Mucosal Immune Responses to Live Attenuated Influenza Vaccine In Healthy Adults
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
1 Tatum Highlands Med Ass PLLC
mi
from
Phoenix, AZ
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
1 Tatum Highlands Med Ass PLLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
7 Heartland Rsrch Ass LLC
mi
from
Wichita, KA
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
7 Heartland Rsrch Ass LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
9 Heartland Research Associates
mi
from
Wichita, KA
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
9 Heartland Research Associates
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
6 Regional Clinical Research Endwell
mi
from
Endwell, NY
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
6 Regional Clinical Research Endwell
mi
from
Endwell, NY
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
4 Benchmark Medical Research
mi
from
Austin, TX
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
4 Benchmark Medical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
12 Tekton Research
mi
from
Georgetown, TX
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
12 Tekton Research
mi
from
Georgetown, TX
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
8 J. Lewis Research Inc.
mi
from
Salt Lake City, UT
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
8 J. Lewis Research Inc.
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
10 Foothill Family Clinic
mi
from
South Cottonwood Heights, UT
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
10 Foothill Family Clinic
mi
from
South Cottonwood Heights, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
11 Jordan River Family Medicine
mi
from
South Jordan, UT
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
11 Jordan River Family Medicine
mi
from
South Jordan, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
42 Hunter Clinical Research
mi
from
Newcastle,
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
42 Hunter Clinical Research
mi
from
Newcastle,
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
5 Broward Research Group Pembroke Pines
mi
from
Hollywood, FL
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
5 Broward Research Group Pembroke Pines
mi
from
Hollywood, FL
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
2 Mercy Health Research
mi
from
Saint Louis, MO
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
2 Mercy Health Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated:  12/31/1969
3 Saint Louis University
mi
from
Saint Louis, MO
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.
Status: Enrolling
Updated: 12/31/1969
3 Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated:  12/31/1969
3 Meridian Clinical Research
mi
from
Miami, FL
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated: 12/31/1969
3 Meridian Clinical Research
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated:  12/31/1969
7 Heartland Research Associates
mi
from
Newton, KA
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated: 12/31/1969
7 Heartland Research Associates
mi
from
Newton, KA
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated:  12/31/1969
5 Heartland Research Associates
mi
from
Wichita, KA
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated: 12/31/1969
5 Heartland Research Associates
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated:  12/31/1969
9 Heartland Research Associates
mi
from
Wichita, KA
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated: 12/31/1969
9 Heartland Research Associates
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated:  12/31/1969
1 Saint Louis University
mi
from
Saint Louis, MO
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated: 12/31/1969
1 Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated:  12/31/1969
6 Meridian Clinical Research
mi
from
Omaha, NE
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated: 12/31/1969
6 Meridian Clinical Research
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated:  12/31/1969
10 Tekton Research
mi
from
Georgetown, TX
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.
Status: Enrolling
Updated: 12/31/1969
10 Tekton Research
mi
from
Georgetown, TX
Click here to add this to my saved trials